Navigation Links
Vista Partners Initiates Coverage on ADVENTRX Pharmaceuticals, Inc.; Target Price $7.50
Date:6/22/2011

SAN FRANCISCO, June 22, 2011 /PRNewswire/ -- Vista Partners announced today that it has initiated coverage on ADVENTRX Pharmaceuticals, Inc. (AMEX: ANX) ("The Company" or "ANX"); with a twelve month target price of $7.50. Ross Silver, Principal Analyst at Vista Partners stated, “ANX has a diverse late stage clinical pipeline with two clinical candidates that could serve multi-billion dollar markets and one candidate with a Prescription Drug User Fee Act, or PDUFA, goal date of September 1, 2011 that could lead to approval by FDA as early as this year. ANX is developing a study protocol for ANX-514, a novel emulsion formulation of the chemotherapy drug docetaxel which serves a multi-billion dollar market. The Company is preparing ANX-514 for submission to the FDA and intends to continue discussions with the FDA regarding the planned Phase 3 clinical study and other requirements for approval of ANX-514. The company is developing its protocol for a pivotal Phase III trial scheduled to begin in 2012." Mr. Silver continues, "In April 2011, ANX completed the acquisition of SynthRx, Inc. SynthRx's lead product candidate is a novel, purified, rheologic and antithrombotic compound, purified poloxamer 188, which ANX is developing as ANX-188. Initially, ANX is developing ANX-188 as a first-in-class treatment for pediatric patients with sickle cell disease in acute crisis and, if ANX is able to reach agreement with FDA on a study protocol on a timely basis, ANX may initiate a Phase 3 clinical trial of ANX-188 for that indication in 2012." Mr. Silver concludes, "In November 2010, ANX submitted a new drug application, or NDA, for Exelbine™, or ANX-530, a novel emulsion formulation of the chemotherapy drug vinorelbine (Navelbine®), to the U.S. Food and Drug Administration, or FDA, and in Jan
'/>"/>

SOURCE Vista Partners
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
3. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
4. Synvista Collaboration Demonstrates in Preclinical Studies the Mechanism for Defective Cholesterol Transport in Patients with Diabetes
5. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
6. Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure
7. NeoVista, Inc. Presents New Data on Its Novel Wet AMD Therapy at AAO
8. Siemens Healthcare Diagnostics Launches B12, Folate, and Ferritin Tests on Its Dimension vista Intelligent Lab System
9. NeoVista Presents One Year Data on Novel Wet AMD Therapy at Macula Society
10. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
11. FDA Grants NeoVistas Request to Expand CABERNET Trial to 30 Sites in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Calif., July 31, 2014 STAAR Surgical Company ... and marketer of implantable lenses and delivery systems for ... ended July 4, 2014 of $20.0 million, a 10% ... of 2013. On a constant currency basis, revenues grew ... the second quarter of 2013.  The effect of foreign ...
(Date:7/31/2014)... 2014 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... the quarter ended June 30, 2014. Financial Results ... Revenue Total revenue for the quarter ended June 30, ... quarter ended June 30, 2013 primarily due to IMBRUVICA ® ... Total revenue for the six months ended June 30, ...
(Date:7/31/2014)... -- UBM Medica US announces that Cancer Network ... exclusive slide shows dealing with communication in the oncology ... Cancer Network, the online home ... and podcasts about the latest clinical findings. Among the ... , End-of-life care is challenging for even the most ...
Breaking Medicine Technology:STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6
... Imaging announced today that it has received FDA 510(k) ... Analyzer® System to assess coronary branch vessels in addition ... artery disease (CAD). The clearance is the third for ... tool that automatically detects significant (50 percent and over) ...
... Medical, Inc., a private sports medicine device company specializing ... immediately, David B. Springer will succeed James Hart as ... Executive Chairman due to health reasons. Hart, ... CEO since the company,s inception in 2005, will continue ...
Cached Medicine Technology:Rcadia COR Analyzer System Receives Expanded FDA Clearance to Rule Out Coronary Artery Disease in Coronary Branch Vessels 2Cayenne Medical, Inc. Appoints David B. Springer President & CEO 2Cayenne Medical, Inc. Appoints David B. Springer President & CEO 3
(Date:7/31/2014)... Most mommy blogs are simple family journals, ... to attract all mothers from all walks of life. ... whether its high fashion or child rearing. When Felicia ... the Internet was so segmented. “I found myself visiting ... and then search Google to get information on another. ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 A ... Music” EXPO in Hollywood introduced country artist/writer-producer Jimmy ... products for musicians. Etymotic is an innovator in ... Earplugs. Since their introduction in 2012, Etymotic’s Music•PRO® ... adapting to unsafe sound levels and restoring natural ...
(Date:7/31/2014)... (HealthDay News) -- Transplant surgeons often feel emotionally ... burnout, a new study suggests. Nearly half ... having a low sense of personal accomplishment and ... exhausted, researchers found. "Burnout is common in ... co-author Dr. Marwan Abouljoud, director of the Henry ...
(Date:7/31/2014)... Joseph M. Lee, M.D., M.S., R.P.V.I, has ... leading provider of quality cardiovascular and internal medicine services ... Lee is a board certified cardiologist with a focus ... to his position at CDHV, Dr. Lee is an ... University Medical Center. Dr. Lee is board certified in ...
(Date:7/31/2014)... Women in the Los Angeles area ... financial future. The Independent Woman , a leader ... 6 upcoming Los Angeles area events. , These ... input from Kim Kiyosaki, a successful investor, entrepreneur, and ... is passionate about women’s financial education. , Now, the ...
Breaking Medicine News(10 mins):Health News:Mommylish Launches Its Website 2Health News:Country Star Jimmy Robbins Now Using Etymotic’s MusicPRO Electronic Earplugs 2Health News:Burnout Common Among Transplant Surgeons, Study Reveals 2Health News:ColumbiaDoctors of the Hudson Valley Welcomes Joseph M. Lee, M.D., M.S., R.P.V.I. 2Health News:ColumbiaDoctors of the Hudson Valley Welcomes Joseph M. Lee, M.D., M.S., R.P.V.I. 3Health News:The Independent Woman to Offer Financial Workshops in the Los Angeles Area - Developed by Women for Women 2
... HealthDay Reporter , MONDAY, May 2 (HealthDay News) ... infants is a surprisingly common practice, new research finds, but ... babies. The study, conducted by the U.S. Food ... are given botanical supplements or teas during their first year ...
... long sought a way to directly measure the brain,s temperature ... developed a way to get the brain,s precise temperature with ... a patient,s head, according to findings presented May 1 at ... "This is the first time that anyone has presented ...
... all counts, the 54-year-old man who collapsed on a ... died. He,d suffered a heart attack, and even though ... shocks with a defibrillator, the man was without a ... cardiac arrest ( http://www.mayoclinic.org/heart-attack/ ), reported first in ...
... , MONDAY, May 2 (HealthDay News) -- Exercising ... finds. The researchers looked at students in grades 1 ... who took part in a program that incorporated physical activity ... a week. Before the study, the students had 40 minutes ...
... have shown that blood-thinning medications, such as aspirin, can ... rising prostate-specific antigen (PSA) levelthe risk of metastasis and ... although very telling, have all emphasized the need for ... Cancer Center having concluded the largest study on this ...
... April 30 (HealthDay News) -- A new study finds that ... may predict increased arterial stiffness, which is associated with cardiovascular ... to pump blood and are also associated with a buildup ... flow and lead to a heart attack. In this ...
Cached Medicine News:Health News:Study Questions Giving Babies Botanical Supplements, Teas 2Health News:Study Questions Giving Babies Botanical Supplements, Teas 3Health News:Researchers develop device to measures brain temperature non-invasively 2Health News:Mayo Clinic CPR efforts successful on man with no pulse for 96 minutes 2Health News:Exercising While Learning Boosts Test Scores, Study Finds 2Health News:Researchers find that aspirin reduces the risk of cancer recurrence in prostate cancer patients 2
... Independent controls for Digital ... stainless steel front. Anodized aluminum ends. ... stainless steel floor. , Oversized refrigeration ... 10C , Positive seal self-closing doors. ...
... The F340 is a basic laboratory ... compensated pH results can be obtained when ... a 3-in-1 electrode. • Fast and easy ... buffer recognition for five buffers (pH 1.68, ...
... The F340 is a basic laboratory ... compensated pH results can be obtained when ... a 3-in-1 electrode. • Fast and easy ... buffer recognition for five buffers (pH 1.68, ...
... dual-monochromator, multi-detection microplate reader with a ... reading capability. Detection modalities include absorbance ... and have optical performance comparable to ... Endpoint, kinetic, spectrum and area-well scanning ...
Medicine Products: